The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer?

Cancer Cell. 2002 Nov;2(5):349-50. doi: 10.1016/s1535-6108(02)00187-3.

Abstract

The recent finding of overexpression of the polycomb group transcriptional repressor EZH2 in prostate cancer raises the possibility that transcriptional regulation at the chromatin level may play a role in the development of the metastatic phenotype and suggests new avenues of exploration with respect to patient stratification and therapeutics.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor*
  • DNA-Binding Proteins
  • Enhancer of Zeste Homolog 2 Protein
  • Gene Expression Profiling
  • Gene Expression Regulation
  • Humans
  • Male
  • Oligonucleotide Array Sequence Analysis
  • Polycomb Repressive Complex 2
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / secondary*
  • Prostatic Neoplasms / surgery
  • Proteins / analysis
  • Proteins / metabolism*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Repressor Proteins / genetics*
  • Repressor Proteins / physiology*
  • Transcription Factors
  • Transcription, Genetic
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • DNA-Binding Proteins
  • Proteins
  • RNA, Messenger
  • Repressor Proteins
  • Transcription Factors
  • EZH2 protein, human
  • Enhancer of Zeste Homolog 2 Protein
  • Polycomb Repressive Complex 2